期刊文献+

美罗华联合CHOP治疗B细胞性非霍奇金淋巴瘤的临床研究 被引量:13

Clinical study of rituximab combining with CHOP treating B cell non-Hodgkin lymphoma
下载PDF
导出
摘要 目的:评价美罗华与CHOP联合治疗B细胞性非霍奇金淋巴瘤的临床效果及不良反应。方法:用同期对照的前瞻性研究方法,将22例B细胞性非霍奇金淋巴瘤患者分为治疗组和对照组,治疗组11例用CHOP方案(环磷酰胺、阿霉素、长春新碱和泼尼)联合美罗华治疗,对照组11例单用CHOP方案。所有病例21 d为1个治疗周期,6个周期后评价。将两组患者按国际淋巴瘤预后因子指数分为中低危组和高危组,分析其疗效与预后。结果:治疗组完全缓解率达72.7%,总有效率90.9%;对照组完全缓解率为36.4%,总有效率为54.5%,两组疗效差异有统计学意义(P<0.001)。结论:美罗华联合CHOP方案治疗CD20+的B细胞性非霍奇金淋巴瘤疗效显著,不良反应与单纯化疗相似,可作为该病目前的首选方案。 Objective To evaluate the therapeutic effects and side-effects of rituximab combining with CHOP on B cell non-Hodgkin lymphoma. Methods A prospective study with concurrent control group was adopted. 22 cases with B cell non-Hodgkin lymphoma were divided into 2 groups. The 11 cases in research group (rituximab group)were administered rituximab combining with CHOP( cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen. The remaining 11 cases in the control group were treated with CHOP regimen only. All cases were received a course of 21 d and were evaluated after 6 coueses. The two groups were divided into high-risk and low-inter-mediate-risk subgroups according to the international prognosis index(IPI). Then we analyzed the relationship between the effects and IPI. Results The complete remission(CR) rate and total effective rate in rituximab group were 72.7% and 90.9% respectively,while those corresponding rates in control group were 36.4% and 54.5% respectively. The therapeutic differences between two groups showed statistical significance ( P 〈 0. 001 ). Conclusion Comparing with CHOP regimen chemotherapy, rituximab combining CHOP regimen showes higher therapeutic effect. The side-effects were concordant in the two groups. Rituximab combining CHOP regimen should be the first choice in treating B cell non-Hodgkin lymphoma.
出处 《东南大学学报(医学版)》 CAS 2007年第5期371-373,共3页 Journal of Southeast University(Medical Science Edition)
关键词 B细胞性非霍奇金淋巴瘤 关罗华 CHOP方案 CD20^+ B cell non-Hodgkin lymphoma rituximab CHOP CD20^+
  • 相关文献

参考文献6

  • 1叶煌阳,张映红.美罗华联合化疗治疗恶性淋巴瘤14例报告[J].临床肿瘤学杂志,2005,10(5):529-531. 被引量:9
  • 2The Intemationa Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin' s lymphoma [ J ]. N Engl J Med, 1993,329:987.
  • 3MALONEY D G, SMITH B, ROSE A. Rituximab : mechanism of action and resistance [ J ]. Semin Onod, 2002,29 ( 1 Suppl 2 ) : 2-9.
  • 4孙燕,何友兼,许立功,勇威本,周立强,李维廉,李丽庆,叶小平,张和平,陈荣楷,朱军.美罗华治疗B细胞淋巴瘤Ⅱ期临床验证报告[J].中国新药杂志,1999,8(12):822-824. 被引量:27
  • 5COIFFIER B, HAIOUN C, KETI'ERER N, et al. Rituximab( anti CD20 monoclonal antibody)for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase Ⅱ study [ J ]. Blood, 1998,92 (6) : 1927-1932.
  • 6WILSON W H,GUTIERREZ M O, CONNOR P, et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose adjusted EPOCH-R[ J]. Semin Oncol,2002,29 (2) :41-47.

二级参考文献7

  • 1孙燕.恶性淋巴瘤的综合治疗[J].齐鲁肿瘤杂志,1996,3(2):92-93. 被引量:2
  • 2孙燕 王奇路.绪论.恶性淋巴瘤的诊断与治疗[M].北京:北京医科大学,中国协和医科大学联合出版社,1997.1-8.
  • 3孙燕 张天译 等.恶性淋巴瘤.肿瘤学[M].天津:天津科学技术出版社,1996,2.362.
  • 4王奇璐 孙燕 等.恶性淋巴瘤.实用肿瘤内科学[M].北京:人民卫生出版社,1998.393-408.
  • 5李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:869
  • 6Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma[J].N Engl J Med, 2002,346:235-242.
  • 7Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy[J]. J Clin Oncol, 1999,17:268-276.

共引文献34

同被引文献75

引证文献13

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部